Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
48
currently held
Exits tracked
15
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capital
Elaia PartnersadminCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway2 weeks agoCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway
adminLauxera Capital PartnersadminBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board1 month agoBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board
admin60 companies matching · Page 2 of 2
| Company | Sector | Geo | Investor | Entry | Hold | Status | Buyer | MOIC | |
|---|---|---|---|---|---|---|---|---|---|
Epoqe Pharma Lundbeckfonden BioCapital | Lundbeckfonden BioCapital | 2021 | 5yr | Active | – | – | |||
Gastrotech Pharma Nordic Biotech K/S | Nordic Biotech Advisors | 2003 | 23yr | Active | – | – | |||
GlycoSpot Spring Nordic | Spring Nordic | 2014 | 12yr | Active | – | – | |||
Henlez Eir Ventures I | Eir Ventures | 2022 | 4yr | Active | – | – | |||
Notify Therapeutics Lundbeckfonden BioCapital | Lundbeckfonden BioCapital | 2021 | 5yr | Active | – | – | |||
Novonesis Novo Holdings Principal Investments | Novo Holdings | 2000 | 26yr | Active | – | – | |||
RheumaLogics Novo Holdings Seed Investments | Novo Holdings | 2024 | 2yr | Active | – | – | |||
Synklino EIFO (direct equity) | Eifo | 2020 | 6yr | Active | – | – | |||
Unshackled CVX Ventures | CVX Ventures | 2025 | 1yr | Active | – | – | |||
Vesper Bio Lundbeckfonden BioCapital | Lundbeckfonden BioCapital | 2012 | 14yr | Active | – | – |
Epoqe Pharma
Lundbeckfonden BioCapital
DenmarkSector
Biotech
InvestorLundbeckfonden BioCapital
Entry
2021
Hold
5yr
Gastrotech Pharma
Nordic Biotech K/S
DenmarkSector
Biotech
InvestorNordic Biotech Advisors
Entry
2003
Hold
23yr
GlycoSpot
Spring Nordic
DenmarkSector
Biotech
InvestorSpring Nordic
Entry
2014
Hold
12yr
Henlez
Eir Ventures I
DenmarkSector
Biotech
InvestorEir Ventures
Entry
2022
Hold
4yr
Notify Therapeutics
Lundbeckfonden BioCapital
DenmarkSector
Biotech
InvestorLundbeckfonden BioCapital
Entry
2021
Hold
5yr
Novonesis
Novo Holdings Principal Investments
DenmarkSector
Biotech
InvestorNovo Holdings
Entry
2000
Hold
26yr
RheumaLogics
Novo Holdings Seed Investments
DenmarkSector
Biotech
InvestorNovo Holdings
Entry
2024
Hold
2yr
Synklino
EIFO (direct equity)
DenmarkSector
Biotech
InvestorEifo
Entry
2020
Hold
6yr
Unshackled
CVX Ventures
DenmarkSector
Biotech
InvestorCVX Ventures
Entry
2025
Hold
1yr
Vesper Bio
Lundbeckfonden BioCapital
DenmarkSector
Biotech
InvestorLundbeckfonden BioCapital
Entry
2012
Hold
14yr